Please use this identifier to cite or link to this item: doi:10.22028/D291-37695
Volltext verfügbar? / Dokumentlieferung
Title: Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer : Results from the International Robotic Cystectomy Consortium
Author(s): Gopalakrishnan, Dharmesh
Elsayed, Ahmed S.
Hussein, Ahmed A.
Jing, Zhe
Li, Qiang
Wagner, Andrew A.
Aboumohamed, Ahmed
Roupret, Morgan
Balbay, Derya
Wijburg, Carl
Stöckle, Michael
Dasgupta, Prokar
Khan, Muhammad Shamim
Wiklund, Peter
Hosseini, Abolfazl
Peabody, James
Shigemura, Katsumi
Trump, Donald
Guru, Khurshid A.
Chatta, Gurkamal
Language: English
Title: International Journal of Urology
Volume: 29 (2022)
Issue: 3
Pages: 197-205
Publisher/Platform: Wiley
Year of Publication: 2021
Free key words: bladder cancer
chemotherapy
muscle-invasive
neoadjuvant
oncological outcomes
recurrence
recurrences
robot-assisted radical cystectomy
survival
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Objectives To analyze the impact of neoadjuvant chemotherapy on survival and recurrence patterns in muscle-invasive bladder cancer after robot-assisted radical cystectomy. Materials and methods The International Robotic Cystectomy Consortium database was reviewed to identify patients who underwent robot-assisted radical cystectomy for muscle-invasive bladder cancer between 2002 and 2019. Survival outcomes, response rates, and recurrence patterns were compared between patients who received neoadjuvant chemotherapy and those who did not. Survival distributions were estimated using Kaplan–Meier analyses and compared using the log-rank test. Results A total of 1370 patients with muscle-invasive bladder cancer were identified, of whom 353 (26%) received neoadjuvant chemotherapy. After a median follow-up of 27 months, neoadjuvant chemotherapy recipients had higher 3-year overall survival (74% vs 57%; log-rank P < 0.01), 3-year cancer-specific survival (83% vs 73%; log-rank P = 0.03), and 3-year relapse-free survival (64% vs 48%; log-rank P < 0.01). Neoadjuvant chemotherapy was a predictor of higher overall survival, cancer-specific survival, and relapse-free survival in univariate but not multivariate analysis. Pathological downstaging (46% vs 23%; P < 0.01), complete responses (24% vs 8%; P < 0.01), and margin negativity (95% vs 91%; P < 0.01) at robot-assisted radical cystectomy were more common in the neoadjuvant chemotherapy group. Neoadjuvant chemotherapy recipients had lower distant (15% vs 22%; P < 0.01) but similar locoregional (12% vs 13%; P = 0.93) recurrence rates. Conclusions In this analysis from a large international database, patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before robot-assisted radical cystectomy had higher rates of survival, pathological downstaging, and margin-negative resections. They also experienced fewer distant recurrences.
DOI of the first publication: 10.1111/iju.14749
URL of the first publication: https://onlinelibrary.wiley.com/doi/10.1111/iju.14749
Link to this record: urn:nbn:de:bsz:291--ds-376954
hdl:20.500.11880/34100
http://dx.doi.org/10.22028/D291-37695
ISSN: 1442-2042
0919-8172
Date of registration: 25-Oct-2022
Description of the related object: Supporting Information
Related object: https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fiju.14749&file=iju14749-sup-0001-Supinfo.docx
Faculty: M - Medizinische Fakultät
Department: M - Urologie und Kinderurologie
Professorship: M - Prof. Dr. Michael Stöckle
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
There are no files associated with this item.


Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.